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Abstract
Background: The ENU Mouse Mutagenesis Project aims
at a large-scale, systematic production of mouse mu-
tants using the alkylating agent ethyl-nitrosourea (ENU).
Offspring of mutagenized mice are subjected to a multi-
parameter screen to detect alterations in various pheno-
types with the ultimate goal of identifying novel genes
relevant for the expression of the phenotype. Using this
approach, we have analyzed plasma IgE concentrations
to identify mouse mutants with aberrant plasma IgE
levels. Methods and Results: ENU-mutagenized male
C3HeB/FeJ were mated to wild-type females to produce
F1 offspring. F1 animals were analyzed for alterations in
their plasma IgE concentrations that showed a dominant
mode of inheritance, or bred further to screen for reces-
sive phenotypes. Plasma IgE concentrations were deter-
mined by ELISA and a normal range for plasma IgE was
established using C3HeB/FeJ wild-type animals. So far
we have tested 6568 F1 animals. Repeated testing con-
firmed a stable aberrant IgE phenotype in 124 animals.
To confirm the genetic basis of the observed phenotype,
these mice were subjected to confirmation crossing. Cur-
rently we have established 9 independent mutant mouse
lines (3 with high plasma IgE and 6 with plasma IgE
below detection limit) that have been genetically con-
firmed and additional 24 variant mouse lines are current-
ly undergoing confirmation testing. Conclusion: ENU
mouse mutagenesis allowed us to generate and identify
mouse mutants with aberrant plasma IgE levels, which
may be used to characterize novel genes involved in IgE
regulation and may serve as animal models for IgE-
mediated diseases.
Copyright © 2001 S. Karger AG, Basel
Introduction
Epidemiological studies on allergic diseases show a
prevalence of 10–20% in the general population and a sig-
nificant increase over the last decades [1]. IgE-mediated
allergies have a multifactorial etiology, where a genetic
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predisposition, determined by complex interaction be-
tween major and minor genes, combined with environ-
mental factors, leads to the manifestation of the disease.
Different strategies have been employed to study the
genetics of atopy, such as linkage analysis using the candi-
date gene approach, genome-wide scans for linkages of
positional genes and disease manifestation, or identifica-
tion of polymorphisms in candidate genes that lead to
structural or functional alterations associated with the
disease [reviewed in 2]. Today, more than seven chromo-
somal regions have been linked to the manifestation of
atopy, many of which contain a number of unknown
genes. With the sequence data of the human genome
being available to the scientific community in the nearest
future, new strategies have to be employed to learn about
the function of novel genes. Model organisms such as dro-
sophila, zebrafish or mice have served as major tools for
functional genome analysis. In this context mice are the
most powerful mammalian system due to the short gener-
ation time, large litter size, cost-effective housing and the
availability of technologies that allow the generation of
mutants for every gene that has been cloned. In addition,
random genome-wide mutagenesis can be employed to
generate mouse mutants which can be identified by
screening for abnormal phenotypes. Taking this ap-
proach, the ENU Mouse Mutagenesis Screen within the
German Human Genome Project (DHGP) aims at a
large-scale systematic production of mouse mutants by
chemical mutagenesis using the alkylating agent ethyl-
nitrosourea (ENU) [3]. Offspring of mutagenized mice are
subjected to a broad range of screening procedures to
detect abnormal phenotypes. Standard breeding strategies
are used to test for the inheritance of the observed pheno-
types and chromosomal mapping is used to identify novel
candidate genes. Due to the conserved synteny among
mammalian species, mapping of the mutant loci to mouse
chromosomal region allows to predict the position of the
corresponding human gene and therefore provides imme-
diate access to potential human candidate genes for a
wide range of diseases.
Here we report the results of our screen analyzing plas-
ma IgE concentrations in mutagenized mice that allowed
us to identify 9 dominant mutant mouse lines with abnor-
mal IgE levels.
Materials and Methods
Ten- to 14-week-old male C3HeB/FeJ mice (Jackson Laborato-
ries, Bar Harbor, Me., USA) were mutagenized by intraperitoneal
injection of ENU (160 mg/kg) and crossed to wild-type C3HeB/FeJ
females as recently described in detail [4]. Mice were housed under
specific pathogen-free conditions and used according to institutional
guidelines. F1 offspring of ENU-treated mice were screened for alter-
ations in plasma IgE concentrations that followed dominant mode of
inheritance, or bred further to study recessive phenotypes. Blood
samples were taken from 12-week-old F1 animals or wild-type con-
trols by puncturing the retroorbital plexus under ether anesthesia.
Plasma was analyzed using an isotype-specific sandwich ELISA for
murine IgE with a lower detection limit of 1 ng/ml. In brief, 96-well
microtiter plates were coated with polyclonal sheep anti-mouse IgE
(The Binding Site, Birmingham, UK), loaded with purified mouse
IgE standards (Clone-IgE-3, Pharmingen, Heidelberg, Germany) and
mouse plasma samples at dilutions of 1:4 to 1:40 and developed
using biotinylated rat anti-mouse IgE (Clone R35-118, Pharmingen),
streptavidin peroxidase (Calbiochem, La Jolla, Calif., USA), tetra-
methylbenzidine (Fluka, Deisenhofen, Germany) and analyzed with
a standard microwell ELISA reader at 450 nm. Plasma IgE concen-
trations were considered abnormal if being below the 2nd or above
the 98th percentile of the plasma IgE levels obtained from a C3HeB/
FeJ wild-type population. F1 animals with abnormal plasma IgE con-
centrations were tested repeatedly (3 times within 6–8 weeks) to
ensure a stable abnormal phenotype. The inheritance of dominant
phenotypes was tested by backcrossing F1 animals with aberrant
plasma IgE levels to wild-type C3HeB/FeJ mice and screening the
offspring (G2) for the penetrance of the phenotype.
Results
In order to establish a normal range for plasma IgE
concentrations 12-week-old wild-type C3HeB/FeJ mice
(n = 315) were analyzed. The plasma IgE levels in the
wild-type population followed a normal distribution (data
not shown). The plasma IgE concentration (mean B SD)
in male C3HeB/FeJ mice was significantly lower than in
female (42.2 B 25 ng/ml; n = 152 vs. 86.12 B 59 ng/ml;
n = 163; p ! 0.001; nonpaired Student’s t test) (fig. 1a).
Using the 2nd and 98th percentile of the wild-type popu-
lation the normal range for plasma IgE was defined as 7–
113 ng/ml for male and 12–254 ng/ml for female C3HeB/
FeJ mice at 12 weeks of age. In a subgroup of wild-type
males (n = 16) and females (n = 9) IgE plasma concentra-
tions were analyzed over time and found to be relatively
stable, only showing minor fluctuations as the animals
grew older (fig. 1b).
Using the IgE normal range obtained in the wild-type
population, F1 offspring of ENU-mutagenized mice were
screened for abnormal plasma IgE levels at the age of 12
weeks. So far we have tested 6,568 F1 animals and identi-
fied 124 animals with abnormal IgE levels. Repeated test-
ing (3 times with 2-week intervals) confirmed a stable
aberrant IgE phenotype. To confirm the genetic basis of
the observed phenotype, these mice were backcrossed to
wild-type animals and the offspring (G2) were tested for
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Fig. 1. Plasma IgE concentration in male
(M) and female (F) C3HeB/FeJ wild-type
mice. Plasma IgE concentrations were signif-
icantly lower in male (n = 152) as compared
to female (n = 163) C3HeB/FeJ (p ! 0.001)
(a) and showed only minor fluctuations over
time as analyzed in a subgroup of male (n =
16) and female (n = 9) C3HeB/FeJ mice (b).
Fig. 2. a Plasma IgE concentrations in F1
offspring of ENU-mutagenized mice ana-
lyzed from January 1998 to January 2000.
Values for females (X) and males ($) are
reported as mean B SEM (20 ! n ! 225/
month). Percentiles of the plasma IgE con-
centrations in the F1 population (n = 6,568)
are indicated by dotted lines as female 98th
(W W W W W), male 98th (- - - - -) and female/male 2nd
(- W W - W W -) percentile. Plasma IgE concentra-
tions of individual male (d) and female (o)
F1 founder animals which gave rise to a
genetically confirmed IgE mutant line were
below and above the 2nd and 98th percentile
of the F1 population. b Representative ex-
ample of a successful confirmation cross.
Circles and squares represent female and
male mice, respectively; filled symbols indi-
cate animals displaying the altered pheno-
type. WT = Wild-type.
the penetrance of the observed phenotype (confirmation
crossing). Currently we have completed 73 confirmation
crosses and successfully established 9 independent mu-
tant mouse lines with abnormal plasma IgE levels that
have been genetically confirmed. Three of them show
increased plasma IgE levels between 400 and 700 ng/ml
and 6 of them display plasma IgE levels below detection
limit of the assay (fig. 2a). In 64 confirmation crosses an
inheritance of the abnormal IgE level was not found; 27
were lost due to sterility or lack of breeding and 24 addi-
tional confirmation crosses are still ongoing. In selected
mouse lines we tested if the observed phenotype was also
transmitted to the third generation (G3) by backcrossing a
G2 animal that displayed the phenotype to a wild-type
animal (fig. 2b). The phenotype of the F1 animal ‘IgE
Low 5’ (IgE levels below detection limit) was displayed by
4 of 11 G2 offspring and by 7 of 13 G3 offspring investi-
gated, which corresponds to a penetrance of 72 and 100%,
respectively.
Discussion
Genome-wide ENU mouse mutagenesis and subse-
quent screening of multiple clinically relevant parameters
has yielded a large number of mouse mutants displaying a
variety of phenotypes [4]. As a parameter relevant for
allergic diseases we have screened plasma IgE levels of
mutagenized mice and successfully established a number
of mutant mouse lines with abnormal plasma IgE concen-
trations.
The F1 animals analyzed by us were screened in paral-
lel for a large panel of immunological parameters (Dr.
Flaswinkel and Dr. Pfeffer, Department of Microbiology
and Immunology, Technical University Munich) which
allowed us to look for mutants with defects in more than
one isotype. Interestingly, none of the founder animals of
our IgE mutant lines showed abnormalities in plasma lev-
els of IgG1, IgG2a, IgG3, IgA or IgM. In addition, the
animals did not display abnormalities in the composition
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of peripheral blood lymphocyte subpopulations [B cells, T
cells (CD4, CD8), NK cells] [Flaswinkel and Pfeffer, pers.
commun.] indicating that the abnormal plasma IgE con-
centrations were not due to gross changes at a cellular
level.
Due to the requirement of blood and tissue samples for
multiple other screens, none of the F1 progeny was avail-
able for further functional characterization of the IgE
response (e.g. after allergen sensitization). With indepen-
dent IgE mutant lines at hand these issues can now be
addressed. Similar to a recently characterized sponta-
neous mouse mutant with IgE hyperresponsiveness [5],
our IgE high mutants may yield novel animal models for
IgE-mediated allergies in humans. In addition IgE mutant
lines are now available to identify mutant loci. Chromo-
somal mapping will be performed using standard out-
cross/backcross breeding strategies and an already estab-
lished panel of polymorphic markers between C3HeB/FeJ
and C57BL/6JIco mice with a genome-wide spacing of
less than 20 cM. A number of mutants generated by ENU
mutagenesis have already been mapped in this way [4],
e.g. a cataract mutant was mapped to chromosome 11 in a
position which makes the ßA3/A1-crystallin encoding
gene Cryba-1 an excellent candidate gene in which a sin-
gle point mutation has been identified [6]. Our work clear-
ly shows that phenotype-oriented mutagenesis allows an
efficient recovery of mouse mutants with aberrant IgE
levels. Future work will focus on the identification of
responsible genes and the role that these genes might have
in the pathogenesis of allergic disease.
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